Lantern Pharma (LTRN) Total Liabilities (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Total Liabilities came in at $3.8 million in Q1 2026, down 12.56% YoY from $4.3 million in Q1 2025, and down 16.09% on a QoQ basis from $4.5 million in Q4 2025.
Lantern Pharma (LTRN) Total Liabilities (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Total Liabilities data on file, last reported at $3.8 million in Q1 2026.
- Quarterly Total Liabilities fell 12.56% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 12.56% YoY) and the FY2025 annual result came in at $4.5 million, up 2.68% from the prior year.
- Total Liabilities declined to $3.8 million in Q1 2026, from $4.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $5.3 million in Q2 2022 to a low of $2.4 million in Q3 2023.
- A 5-year average of $3.8 million and a median of $3.8 million in 2026 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 299.35% — and 2023, when it sank 40.3%.
- Tracing LTRN's Total Liabilities over 5 years: stood at $2.8 million in 2022, then slipped by 2.09% to $2.7 million in 2023, then soared by 60.02% to $4.4 million in 2024, then gained by 2.68% to $4.5 million in 2025, then retreated by 16.09% to $3.8 million in 2026.
- The last three Total Liabilities figures came in at $3.8 million (Q1 2026), $4.5 million (Q4 2025), and $4.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Lantern Pharma | 26.11 Mn | 26.11 Mn | - | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | 4.50 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.90 Mn |
| Mar 31, 2025 | 4.32 Mn |
| Dec 31, 2024 | 4.38 Mn |
| Sep 30, 2024 | 3.70 Mn |
| Jun 30, 2024 | 4.66 Mn |
| Mar 31, 2024 | 3.97 Mn |
| Dec 31, 2023 | 2.74 Mn |
| Sep 30, 2023 | 2.36 Mn |
| Jun 30, 2023 | 3.17 Mn |
| Mar 31, 2023 | 2.93 Mn |
| Dec 31, 2022 | 2.80 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 5.30 Mn |
| Mar 31, 2022 | 3.09 Mn |
| Dec 31, 2021 | 2.38 Mn |
| Sep 30, 2021 | 1.88 Mn |
| Jun 30, 2021 | 2.82 Mn |